China has approved its first animal biopharmaceutical with fully independent intellectual property, marking a breakthrough in the field of veterinary medicine. 

Developed by VJTbio (Zhejiang) in Xianju county, Taizhou, East China's Zhejiang province, the Fc fusion protein for recombinant pig follicle-stimulating hormone has been granted a national class one new veterinary drug certificate.

The drug, designed to improve breeding efficiency in pigs, offers the advantages of safety, high efficacy, and zero residue. It is positioned as a key solution for intensive and large-scale farming, addressing long-standing challenges in reproduction management. Clinical trials showed that sows treated with the product achieved higher annual farrowing rates and improved the number of pigs weaned per sow per year, reducing costs while boosting farm income.

VJTbio (Zhejiang) operates China's first production line for veterinary antibody and fusion protein drugs. The company has developed integrated solutions that combine the new drug with farm management and biosecurity systems. The product helps resolve issues such as low conception rates in gilts, uneven breeding cycles, and fertility delays in older sows.

As the world's first long-acting, zero-residue recombinant protein drug for animal reproduction, it provides a safe, repeatable option for modern farms. Industry experts note that the approval represents a major step in the global patent strategy of animal pharmaceuticals, with the potential to benefit millions of sows in China and support sustainable livestock development worldwide.